Compare Aspen Aerogels Inc (ASPN) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aspen Aerogels Inc vs Crispr Therapeutics AG — how do they compare? Aspen Aerogels Inc trades at $6.14 (market cap $509.55M), while Crispr Therapeutics AG trades at $53.95 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 10.3× Aspen Aerogels Inc's market cap, and Aspen Aerogels Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| ASPN | CRSP | |
|---|---|---|
Market Cap | $509.55M | $5.23B |
Sector | Technology | Health |
52-Week High | $8.82 | $76.78 |
52-Week Low | $2.57 | $44.34 |
Enterprise Value | $482.96M | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $6.15, down 2.23% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue beat but missed EPS estimates, with a net income margin of -62.45% and negative cash flow. Recent news highlights sequential revenue improvement and a raised European Thermal Barrier outlook for 2026.
Outlook hinges on execution of Q3 revenue guidance of $65-80M and adjusted EBITDA of $7-15M. Risks include persistent losses and competitive pressures, but analyst consensus is strongly bullish with 82.61% buy ratings, suggesting confidence in the recovery trajectory.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
